There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at a uniquely
high risk of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. The pre-emptive
treatment model whereby asymptomatic post-transplant patients are routinely screened
with treatment initiated if found viremic has recently been shown to be superior in
terms of patient mortality when compared to deferring laboratory assessment and treatment
until symptoms emerge. This study analyzes the cost-effectiveness of the pre-emptive
therapy model in patient care dollars per quality-adjusted life years (QALY).